All News

RA Associated Cancer Risk

Save

d Jack Cush, MD

Sep 19, 2023

A large cohort analysis of insured rheumatoid arthritis (RA) patients reveals that RA patients have a 1.69 to 2.08 fold higher risk of developing cancer, especially lymphoma or lung cancer, within 1 year of RA diagnosis.

Read Article

Japanese study of 106 RA pts starting ABA, TCZ or TNFi. Among the 37 starting ABA, 17 were + for HLA-DRB1*04:05 who were uniquely responsive (SDAI50=71%) compared to those without *04:05 haplotype (30%) (p=0.022) https://t.co/3tQz84vK1T https://t.co/XL7aRKCmDx

RheumNow Dr. John Cush ( View Tweet)

Sep 18, 2023

84 #RA pts in remission >1 yr on TNFi showed an increase in flare rate if TNFi tapered to D/C ( 63% TNFi taper group vs 5%) in stable TNFi group). Tapering strategy was not non-inferior to continued Tx; Most regained remission after TNFi reinstatement https://t.co/8idQJhA6bs https://t.co/ZgMcDDLibc

RheumNow Dr. John Cush ( View Tweet)

Sep 10, 2023

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Save

d Jack Cush, MD

Sep 08, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

Read Article

Oral Surveillance Changes in Advanced Therapy Use in RA

Save

d Jack Cush, MD

Sep 06, 2023

The safety of tofacitinib and TNF inhibitors was studied in high risk rheumatoid arthritis (RA) patients in the ORAL Surveillance study, which culminated in an FDA warning in January 2021 on the cardiovascular, cancer and VTE risks associated with JAK inhibitor use.

Read Article

SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/cpfWvKaR1y

RheumNow Dr. John Cush ( View Tweet)

Sep 02, 2023

SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/WCfBzthXvl

RheumNow Dr. John Cush ( View Tweet)

Aug 31, 2023

EHR data on 2172 RA pts Rx w/ Biologicd showed 4 clusters with different outcomes: 1) TNFi persisters (66%), 2) TNFi + ABA (8%), 3) RTX or multiple b/tsDMARDs (13%), 4) mult Rx w/ TCZ predominant (14%). Best CDAI outcomes for #1 > #4 https://t.co/gTYhtzj2pe https://t.co/bA067yjIa2

RheumNow Dr. John Cush ( View Tweet)

Aug 26, 2023

Biologic Adherence and Drug Survival in RA Patients

Save

d Jack Cush, MD

Aug 24, 2023

A real-world rheumatoid arthritis (RA) cohort study from Israel shows significant variability of drug survival using biologic disease-modifying anti-rheumatics drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).

Read Article

Mono- and Oligo- are Different (8.18.2023)

Save

d Jack Cush, MD

Aug 18, 2023

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Read Article

Do TNF inhibitors work in cardiac sarcoid (CS)? PET scan study of 31 CS pts Rx w/ infliximab 13, adalimumab 15, adalimumab 3. Mean pred dose dropped 18.6 to 7.7mg, p = 0.018) & PET improved w/ TNFi and only 4 pts had CV hospitalization during F/U https://t.co/WjAiSVXJWI https://t.co/5tDXNa9Usp

Links:

https://bit.ly/3YK1Uba

Dr. John Cush RheumNow ( View Tweet)

Aug 17, 2023

The Adalimumab Biosimilar Glut

Save

d Jack Cush, MD

Aug 15, 2023

In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.

Read Article

Pizza and Rheumatoid Arthritis (8.11.2023)

Save

d Jack Cush, MD

Aug 11, 2023

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article

Prospective, open-label study compared 19 Takayasu pts on secukinumab vs 34 pts on TNFi . SEC response (Complete/partial) was 53% & the TNFi response was 59% at 3 mos. SEC had 4 pts relapse by wk 48 (median 31 wks(, TNFi had 12 pts relapse. https://t.co/IQDFDmbdBR https://t.co/hIx6qvzAO8

Links:

https://bit.ly/3OPzs44

Dr. John Cush RheumNow ( View Tweet)

Aug 10, 2023

Chinese study of 5530 RA pts found 546 (9.9%) who developed diabetes. DM risk was significantly lower w/ bDMARD (HR 0.51), MTX (HR 0.50) and HCQ (HR 0.52). TNF inhibitors were also protective (HR 0.69). https://t.co/hdkyqFXbbu https://t.co/baQORpq1HP

Links:

https://bit.ly/3YlnfYd

Dr. John Cush RheumNow ( View Tweet)

Aug 08, 2023

HEALTH DISPARITIES: Lancet study shows from 2000-2019, all-cause mortality was signif. higher in the American Indian/Alaska Native (1028/100K) & Blacks (953·/100K) compared to Whites (802); but lower in Asians (442) & Latinos (595) https://t.co/g8Z3h6BYw8 https://t.co/Ckz1L3O0W7

Links:

https://bit.ly/45eZ67L

Dr. John Cush RheumNow ( View Tweet)

Aug 04, 2023

Rheums: Have a rheumatology question or case for Dr. Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/uY9Mwyrsn3

Links:

https://bit.ly/47dWEQJ

Dr. John Cush RheumNow ( View Tweet)

Aug 03, 2023

WHO Safety Study of Five TNF Inhibitors

Save

d Jack Cush, MD

Jul 25, 2023

Large scale analysis of adverse events (AEs) in World Health Organization (WHO) VigiAccess database showed no new safety signals associated with long-standing use of five TNFα inhibitors.

Read Article

Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/vGt12ul6iy https://t.co/044BScmSYc

Links:

https://bit.ly/3K4sy8m

Dr. John Cush RheumNow ( View Tweet)

Jul 21, 2023

BE OPTIMAL study: Bimekizumab vs adalumumab in 702 #PsA pts, showed sustained 52 week ACR50 responses at wk 52: 54% BKZ v 50% ADA; PASI 100 61% BKZ v 48% ADA. Serious AE seen in 6.6% of BKZ patients, 1 death and 7.7% w/ Candida (vs 0.7% w/ ADA) https://t.co/4g3j5OoKyy https://t.co/g4SQubSCXg

Links:

https://bit.ly/3rGd4B0

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2023

Topics

All News

RA Associated Cancer Risk

Save

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Save

Oral Surveillance Changes in Advanced Therapy Use in RA

Save

Biologic Adherence and Drug Survival in RA Patients

Save

Mono- and Oligo- are Different (8.18.2023)

Save

The Adalimumab Biosimilar Glut

Save

Pizza and Rheumatoid Arthritis (8.11.2023)

Save

WHO Safety Study of Five TNF Inhibitors

Save

Do you get our email newsletter?